
UK halts puberty blockers for minors, focuses on research trials
By Lauren Taylor (Reporter), Jake Maslo (Video Editor)
This report was created with support from enhanced software.
Media Landscape
See how news outlets across the political spectrum are covering this story. Learn moreBias Summary
- Enim nostra aliquet donec sit elementum semper eu iaculis vestibulum per a feugiat egestas congue, velit montes maecenas at curabitur etiam vivamus orci cubilia diam laoreet neque.
- Scelerisque cubilia natoque lorem ornare suscipit leo cursus mollis ridiculus sollicitudin, risus iaculis dignissim porttitor orci pulvinar massa ullamcorper feugiat, erat vitae vestibulum nostra nam ligula elementum mattis netus.
- Proin amet magna torquent praesent odio aliquam fames taciti platea sagittis pulvinar montes magnis duis, mus metus parturient ornare lacinia in bibendum feugiat interdum neque volutpat rutrum.
- Natoque placerat venenatis rutrum finibus pharetra interdum pellentesque sapien varius donec auctor vestibulum montes sagittis elit bibendum elementum aenean justo, fermentum nunc dolor magnis vivamus ipsum quam dapibus dignissim mauris erat nisl proin parturient tincidunt ridiculus turpis.
- Dictumst molestie quis donec natoque netus fermentum diam maecenas nisi venenatis, ornare rutrum nam facilisis ex nascetur efficitur dictum magnis.
Bias Distribution
Left
Untracked Bias
The United Kingdom’s National Health Service (NHS) announced Tuesday, March 12, that puberty blockers will no longer be prescribed to children under 18, except within regulated clinical trials. Puberty blockers are utilized to delay the onset of puberty.
According to the agency, these blockers will now only be accessible as part of research trials after a review cited insufficient evidence regarding their safety and effectiveness.

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.
Point phone camera here
The NHS initiated an independent review of gender identity treatments for minors in 2020 in response to a “significant increase” in referrals to the Gender Identity Development Service, which is set to close at the end of March.
Health Minister Maria Caulfield welcomed the decision, emphasizing the safety of children.
Simultaneously, an ongoing consultation on gender services has received over 4,000 responses, underscoring a divided public opinion.
This development is the latest in the contentious treatment, which has also triggered protests in the United States over gender-affirming care in children.
England’s NHS aims to commence a study on the use of puberty blockers by December 2024.
According to BBC, fewer than 100 young people in England currently receive these blockers through the NHS, and their treatment will continue.
[LAUREN TAYLOR]
PUBERTY BLOCKERS WILL NO LONGER BE PRESCRIBED TO CHILDREN UNDER THE AGE OF 18 IN ENGLAND — OUTSIDE OF REGULATED CLINICAL TRIALS, THE COUNTRY’S NATIONAL HEALTH SERVICE ANNOUNCED TUESDAY.
PUBERTY BLOCKERS ARE USED TO DELAY THE EFFECTS OF PUBERTY.
THE AGENCY SAYS THESE BLOCKERS WILL NOW ONLY BE AVAILABLE AS PART OF RESEARCH TRIALS. THE DECISION FOLLOWS A REVIEW CITING INSUFFICIENT EVIDENCE FOR THEIR SAFETY AND EFFECTIVENESS.
THE NHS CALLED FOR AN INDEPENDENT REVIEW OF GENDER IDENTITY TREATMENTS FOR MINORS IN 2020 AMID A “SIGNIFICANT INCREASE” IN REFERRALS TO THE GENDER IDENTITY DEVELOPMENT SERVICE , WHICH IS SCHEDULED TO CLOSE AT THE END OF MARCH.
HEALTH MINISTER MARIA CAULFIELD WELCOMED THE DECISION, EMPHASIZING CHILDREN’S SAFETY.
MEANWHILE, AN ONGOING CONSULTATION ON GENDER SERVICES HAS GARNERED OVER 4,000 RESPONSES, REFLECTING A DIVIDED PUBLIC OPINION.
IT’S THE LATEST DEVELOPMENT IN THE CONTROVERSIAL TREATMENT THAT HAS SPARKED PROTESTS IN THE U.S., AS WELL, OVER GENDER-AFFIRMING CARE IN CHILDREN.
NHS ENGLAND PLANS TO START A STUDY ON PUBERTY BLOCKERS’ USE BY DECEMBER 2024.
FEWER THAN 100 YOUNG PEOPLE IN ENGLAND CURRENTLY RECEIVE THESE BLOCKERS THROUGH THE NHS, AND THEIR TREATMENT WILL CONTINUE, REPORTS THE BBC.
Media Landscape
See how news outlets across the political spectrum are covering this story. Learn moreBias Summary
- Vitae est quam porttitor odio fusce vestibulum malesuada sit turpis sociosqu lorem auctor hendrerit primis, mattis hac sed egestas sapien ultrices vivamus metus ad taciti sagittis felis.
- Vehicula ad diam facilisi bibendum facilisis mi integer neque pulvinar orci, volutpat sit rutrum eleifend metus consectetur elementum nascetur auctor, fringilla dui turpis est interdum suspendisse fusce nisl sodales.
- Gravida iaculis velit class feugiat donec natoque litora condimentum ligula pellentesque consectetur hac eros maximus, viverra ornare convallis bibendum nec a elit auctor nam felis lacinia lacus.
- Diam fermentum habitant lacus aliquet vel nam congue lectus inceptos porttitor mus turpis hac pellentesque efficitur elit fusce magnis ultricies, urna vulputate finibus eros vivamus et blandit netus rutrum aenean fringilla in gravida convallis maecenas pulvinar mauris.
- Curae tincidunt at porttitor diam sodales urna taciti sed euismod habitant, bibendum lacus interdum dis venenatis platea eu luctus eros.
Bias Distribution
Left
Untracked Bias
Straight to your inbox.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.